Table 1.
Experimental design of CCI studies
| Exp | n/group | Treatment (route of administration, frequency, days of dosing)1 | Dose |
|---|---|---|---|
| 1 | 3 (sham), 5 (CCI) | AV411 (i.p., QD, days 10−14 post-surgery) | 3, 15 mg kg−1 |
| 2 | 5−8 | AV411 (i.p., BID, days 10−14 post-surgery) | 2.5, 7.5, 10 mg kg−1 |
| 3 | 4−5 | AV411 ((i.p., BID, days 10−14 post-surgery) | 7.5 mg kg−1 |
| Gabapentin (i.p., BID, days 10−14 post-surgery) | 50 mg kg−1 | ||
| 4 | 7−8 | AV411 (p.o., BID, days 15−19 post-surgery) | 22 mg kg−1 |
| 5 | 4−7 | AV411 (i.t., single, day 10) | 25 μg rat−1 |
| 6 | 5−6 | AV411 (i.p., BID, days 10−16 post-surgery) | 7.5 mg kg−1 |
| Morphine (s.c., BID, days 12−16 post-surgery) | 1 mg kg−1 |
1
Abbreviations: i.p., intraperitoneal; p.o., per os; i.t., intrathecal; s.c., subcutaneous; QD, once daily; BID, twice daily.